LoginSign Up
CRISPR Therapeutics

CRISPR Therapeutics

A biopharmaceutical and gene editing company founded in 2013. CRISPR Therapeutics AG is based in Zug, Switzerland and CRISPR Therapeutics, Inc. is the U.S. subsidiary with R&D operations in Cambridge, Massachusetts and business offices in London, U.K.

CRISPR Therapeutics is developing medicine for serious diseases using the CRISPR-Cas9 platform that co-founder Emmanuelle Charpentier and Jennifer Doudna co-developed and published togehter in Science in 2012 . Charpentier and Doudna were awarded the 2015 Breakthrough Prize in Life Sciences. Charpentier is one of the co-founders and is an advisor to CRISPR Therapeutics which was initially called Inception Genomics AG.

CRISPR Therapeutics’ lead product candidate, CTX001, targets sickle cell disease and beta-thalassemia. Cells are harvested from a patient, treated ex vivo with the CRISPR-Cas9-based therapeutic, and returned to the patient. A clinical trial for CTX001 began in December 2017. Other therapeutic developments include CTX101 and other CAR-T therapies to target cancer. CAR-T therapies are chimeric antigen receptor T cell therapies which are immune cells engineered to find and destroy cancer cells. Hemoglobinopathies and regenerative medicine are other areas they are working in.

CRISPR Therapeutics began separate collaborations with Vertex Pharmaceuticals and Bayer in 2015. The joint venture with Bayer has been named Casebia Therapeutics and focuses of blood disorders, blindness and congenital heart disease.

Timeline

People

Name
Role
Related Golden topics

Emmanuelle Chapentier

Co-Founder, Scientific Advisory Board

Michael Tomsicek

CFO

Rodger Novak

Co-Founder and President

Samarth Kulkarni

CEO

Shaun Foy

Co-Founder, former CFO

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References